MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Anavex Life Sciences Corp

Closed

SectorHealthcare

8.54 6.62

Overview

Share price change

24h

Current

Min

7.75

Max

8.72

Key metrics

By Trading Economics

Income

-491K

-12M

EPS

-0.14

Employees

42

EBITDA

-1.8M

-14M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+255.36% upside

Dividends

By Dow Jones

Next Earnings

8 maj 2025

Market Stats

By TradingEconomics

Market Cap

682M

Previous open

1.92

Previous close

8.54

News Sentiment

By Acuity

24%

76%

62 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Anavex Life Sciences Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 kwi 2025, 23:55 UTC

Hot Stocks

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 kwi 2025, 22:50 UTC

Major Market Movers

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 kwi 2025, 21:08 UTC

Earnings

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 kwi 2025, 21:00 UTC

Earnings

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 kwi 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 kwi 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2 kwi 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 kwi 2025, 23:44 UTC

Top News

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 kwi 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 kwi 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 kwi 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 kwi 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2 kwi 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 kwi 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 kwi 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 kwi 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 kwi 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 kwi 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 kwi 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 kwi 2025, 22:43 UTC

Top News
Acquisitions, Mergers, Takeovers

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 kwi 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 kwi 2025, 21:48 UTC

Top News

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 kwi 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 kwi 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 kwi 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 kwi 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 kwi 2025, 21:04 UTC

Top News

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 kwi 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 kwi 2025, 20:53 UTC

Earnings

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 kwi 2025, 20:52 UTC

Earnings

Kaiser Aluminum Changes Inventory Acctg Methodology

Peer Comparison

Price change

Anavex Life Sciences Corp Forecast

Price Target

By TipRanks

255.36% upside

12 Months Forecast

Average 28.5 USD  255.36%

High 42 USD

Low 15 USD

Based on 2 Wall Street analysts offering 12 month price targets forAnavex Life Sciences Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

7.895 / 8.72Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

62 / 386 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Interest expense on debt

EBITDA

Operating profit

$

About Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.